|
1) Hickey WF. Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol. 1999; 11: 125-37
|
|
|
|
2) Hart MN, Fabry Z. CNS antigen presentation. Trends Neurosci. 1995; 18: 475-81
|
|
|
|
|
|
3) Kobayashi H. Viral xenogenization of intact tumor cells. Adv Cancer Res. 1979; 30: 279-99
|
|
|
|
|
|
4) Moore AE. The oncolytic viruses. Prog Exp Tumor Res. 1960; 1: 411-39
|
|
|
|
|
|
5) Martuza RL, Malick A, Markert JM, et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science. 1991; 252: 854-6
|
|
|
|
|
|
6) Sobol RE, Fakhrai H, Shawler D, et al. Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 1995; 2: 164-7
|
|
|
|
|
|
7) Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007; 5: 67
|
|
|
|
|
|
8) Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004; 27: 452-9
|
|
|
|
|
|
9) De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008; 14: 3098-104
|
|
|
|
|
|
10) Yamanaka R. Cell- and peptide-based immunotherapeutic approaches for glioma. Trends Mol Med. 2008; 14: 228-35
|
|
|
|
|
|
11) Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev. 2009; 32: 265-73
|
|
|
|
|
|
12) Toda M. Glioma antigen. In: Yamanaka R, editor. Glioma: Immunotherapeutic Approaches: Landes Bioscience; 2009
|
|
|
|
|
|
13) Das S, Raizer JJ, Muro K. Immunotherapeutic treatment strategies for primary brain tumors. Curr Treat Options Oncol. 2008; 9: 32-40
|
|
|
|
|
|
14) Izumoto S, Tsuboi A, Oka Y, et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg. 2008; 108: 963-71
|
|
|
|
|
|
15) Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003; 9: 4247-54
|
|
|
|
|
|
16) Toda M. Immuno-viral therapy as a new approach for the treatment of brain tumors. Drug News Perspect. 2003; 16: 223-9
|
|
|
|
|
|
17) Ueda R, Iizuka Y, Yoshida K, et al. Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene. 2004; 23: 1420-7
|
|
|
|
|
|
18) Ueda R, Kinoshita E, Ito R, et al. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. Int J Cancer. 2008; 122: 2274-9
|
|
|
|
|
|
19) Ueda R, Yoshida K, Kawase T, et al. Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int J Cancer. 2007; 120: 1704-11
|
|
|
|
|
|
20) Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol. 1997; 9: 709-16
|
|
|
|
|
|
21) Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94: 1914-8
|
|
|
|
|
|
22) Ueda R, Tsukada O-K, Fusaki N, et al. Identificaion of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer. In press
|
|
|
|
|
|
23) Zalutsky MR, Moseley RP, Benjamin JC, et al. Monoclonal antibody and F(ab')2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res. 1990; 50: 4105-10
|
|
|
|
|
|
24) Wikstrand CJ, Hale LP, Batra SK, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 1995; 55: 3140-8
|
|
|
|
|
|
25) Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007; 7: 675-87
|
|
|
|
|
|
26) Wikstrand CJ, Cole VR, Crotty LE, et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother. 2002; 50: 639-52
|
|
|
|
|
|
27) Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8: 755-68
|
|
|
|
|
|
28) Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer. 2006; 6: 425-36
|
|
|
|
|